Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. Vertex Pharmaceuticals beat analysts’ revenue expectations by 3.2% ...
Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...
Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options become available today, for the April 4th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...
Biotechnology company Vertex Pharmaceuticals (VRTX) reported mixed results for the fourth quarter of 2024. While revenue surpassed analyst expectations, driven by strong demand for its cystic ...
Piper Sandler analyst Christopher Raymond maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $533.00. The company’s shares closed ...
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations , with sales up 15.7% year on year to $2.91 billion. The company ...
Shares of VRTX opened at $453.20 on Tuesday. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a 52-week low of $377.85 ...
Good day, and welcome to the Vertex Pharmaceuticals Fourth Quarter 2024 Earnings Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results